ITP
Clinical trials for ITP explained in plain language.
Never miss a new study
Get alerted when new ITP trials appear
Sign up with your email to follow new studies for ITP, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Matched conditions: ITP
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody drug aims to boost platelets in Hard-to-Treat ITP
Disease control Recruiting nowThis early-phase trial is testing a new drug called budoprutug (TNT119) in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive two IV doses and are monitored for safety, how the drug mov…
Matched conditions: ITP
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC